Determination of platinum originating from carboplatin in human urine and canine excretion products by inductively coupled plasma mass spectrometry.

We present highly sensitive, rapid methods for the determination of Pt originating from carboplatin in human urine and canine urine, feces, and oral fluid. The methods are based on the quantification of Pt by inductively coupled plasma mass spectrometry, and allow quantification of 7.50 ng/L Pt in human and canine urine (in 15 µL of matrix), 15.0 ng/L Pt in canine oral fluid (in 15 µL of matrix), and 0.105 ng/g Pt in canine feces (in 5 µg of matrix). Sample pretreatment mainly involved dilution with appropriate diluents. The performance of the methods fulfilled the most recent FDA guidelines for bioanalytical method validation. Validated ranges of quantification were 7.50 to 1.00 × 10(4) ng/L Pt in human and canine urine, 0.105-30.0 ng/g Pt in canine feces, and 15.0 to 1.00 × 10(4) ng/L Pt in canine oral fluid. Canine urine and oral fluid cannot be easily obtained. Therefore, we also investigated the validity of the usage of human matrix samples for the preparation of calibration standards and quality control samples as alternatives, to be used in future clinical studies. The assays are used to support biomonitoring studies and pharmacokinetic studies in pet dogs treated with carboplatin.

Determination of platinum originating from carboplatin in canine sebum and cerumen by inductively coupled plasma mass spectrometry.

We present highly sensitive, reliable methods for the determination of platinum originating from carboplatin in canine sebum and cerumen. The methods are based on the measurement of platinum by inductively coupled plasma mass spectrometry and allow quantification of 0.15 pg platinum per cm² body surface in canine sebum and of 7.50 pg platinum per sampled ear canal. The sample pretreatment procedure involved extraction of wipe samples followed by dilution with appropriate diluents. The performance of the methods, in terms of accuracy and precision, fulfilled the most recent FDA guidelines for bioanalytical method validation. Validated ranges of quantification were 15.0-1.00 x 104 ng L⁻¹ for platinum in canine sebum extraction solution (corresponding to 15.0 pg per wipe sample or 0.15 pgcm⁻²) and 7.50-1.00 x 104 ng L⁻¹ for platinum in canine cerumen extraction solution (corresponding to 7.50 pg per sampled external acoustic meatus). Canine matrices may not always be obtained in sufficient quantities. Therefore, we also confirmed the legitimacy of the application of human matrix samples for the preparation of calibration standards and quality control samples as alternatives, to be used in future clinical studies. The assays are used to support human biomonitoring studies and pharmacokinetic oncology studies in pet dogs treated with carboplatin.